Johnson & Johnson( JNJ- Free Report) kicked off 2018 pharma earnings on a strong note, beating the Zacks Consensus Estimate on both counts in the first quarter of 2018. The drug and consumer products giant upped its previously issued sales outlook for 2018. Shares were up around 1% in pre-market trading.
J&J Tops Q1 Earnings Estimates, Raises Sales Guidance
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться